Like NOS2A, B3GNT2 likely influences the risk of at least five AADs—including IDDM, RA, Graves’-disease (GD), ankylosing spondylitis (AS), and Crohn’s disease (CD)52,53,54,55,56—and it has not previously been implicated in the development, persistence, and/or resolution of FEIs. Here, B3GNT2 is linked to ankylosing spondylitis.